Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890890 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT00890890 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 263 participants.
The verdict
NCT00890890, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.
Interventions
- DRUG Placebo
- DRUG Avagacestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890890
The ClinicalTrials.gov registry entry for NCT00890890 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00890890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00890890 about?
NCT00890890 is a clinical study titled "A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease". The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.
What is the current status of trial NCT00890890?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2009-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00890890?
The interventions under investigation include: Placebo (DRUG), Avagacestat (DRUG).
Who is sponsoring clinical trial NCT00890890?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.